Inflammatory Bowel Diseases
Cure8 research brief
Why This Matters
Families and clinicians deciding on a first biologic for a child with ulcerative colitis need to know which drugs have pediatric-specific evidence. This review shows infliximab has the strongest pediatric data, while newer biologics/small molecules have less direct pediatric evidence to guide first-line use.
Who Should Pay Attention
Pediatric UC patients and families, pediatric gastroenterologists, and researchers focused on pediatric IBD therapeutics.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
A recent critical review looked at the pediatric evidence for using advanced therapies as first-line biologic/small-molecule treatment in children with ulcerative colitis. Infliximab (an anti‑TNF) has the most robust prospective pediatric data. Evidence for vedolizumab, ustekinumab, and newer selective IL‑23 inhibitors in children is more recent and limited.
Across drug classes, there are few or no direct head‑to‑head trials in biologic‑naïve pediatric patients, so the review emphasizes that efficacy data exist for multiple agents but that evidence to guide which effective drug should be started first for a given child is lacking.
The authors recommend future pediatric studies that provide direct comparative and predictive data to inform individualized first‑line therapy choices.
Keep In Mind
Abstract-level summary only; conclusions reflect the authors' synthesis of pediatric studies and call for more comparative and predictive research. This note does not replace reading the full review or individual studies.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationInflammatory Bowel Diseases
PublisherOxford University Press (OUP)
AuthorsToshihiko Kakiuchi
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedOct 8, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled Trial
This trial tests whether starting with one biologic or targeted therapy versus another (and the sequence of switches) affects remission, safety, and quality of life for people with moderate-to-severe ulcerative colitis —...
Switching Between Anti-TNFs and Other Biologic Drugs in Paediatric Inflammatory Bowel Disease: A Narrative Review and Practical Clinical Guide.
Switching biologics is a frequent and consequential decision in children with IBD; using TDM and a mechanism‑based approach can help choose whether to optimize, switch within class, or change drug class.
Postoperative Complications Associated with Advanced Therapies in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
People with IBD and clinicians often face decisions about whether to stop biologics or small molecules before abdominal surgery.